Biolab provides a wide selection of molecular assays for detecting specific genetic mutations and biomarkers associated with blood cancers. These assays are ideal for precision medicine, as they allow clinicians to tailor treatments based on the unique molecular profile of each patient. With kits targeting markers such as C-KIT, FLT3, NPM1, JAK2, and CALR, our portfolio supports detailed genetic analysis at both qualitative and quantitative levels.

These individual marker kits are highly sensitive and designed for accurate detection even with low DNA/RNA copy numbers. They play a critical role in diagnosis, prognosis, and monitoring minimal residual disease (MRD), ensuring physicians have actionable insights for effective clinical decision-making.